Threshold Pharmaceuticals Inc - Current report filing (8-K)
11 September 2008 - 7:50PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: September 9, 2008
(Date of Earliest Event Reported)
THRESHOLD PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-32979
|
|
94-3409596
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
1300 Seaport Boulevard
Redwood City, California 94063
(Address of Principal Executive Offices)(Zip
Code)
(650) 474-8200
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On September 9, 2008, Threshold Pharmaceuticals,
Inc. (the Company) issued a press release announcing that it had received written communication from the NASDAQ Listing Qualifications Panel indicating that the Company had demonstrated compliance with NASDAQs Minimum Bid Price
Requirement and will accordingly continue to be listed on the NASDAQ Capital Market.
A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01
|
Financial Statements and Exhibits
|
|
|
|
|
|
99.1
|
|
Press Release dated September 9, 2008
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
THRESHOLD PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ J
OEL
A. F
ERNANDES
|
|
|
Joel A. Fernandes
|
|
|
Senior Director, Finance and Controller
|
Date: September 11, 2008
Threshold Pharmaceuticals (MM) (NASDAQ:THLDD)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Threshold Pharmaceuticals (MM) (NASDAQ:THLDD)
Historical Stock Chart
Von Okt 2023 bis Okt 2024
Echtzeit-Nachrichten über Threshold Pharmaceuticals (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Threshold Pharmaceuticals Inc News-Artikel